Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tandem Auto/Allo HCT + Bortezomib in High-Risk MM
NCT00793572Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Oct 2008
- Primary completion
- Oct 2016
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in multiple myeloma (MM), sponsored by Fred Hutchinson Cancer Center. Started Oct 2008; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00793572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00793572.